Table 1.
Demographic, clinical, and radiographic data of the total study cohort.
| Total cohort | IRL patients | Non-IRL patients | p-values IRL vs. Non-IRL | |
|---|---|---|---|---|
| Number of analyzed patients/with IRLs | 29 | 21 | 8 | |
| Gender (f/m) | 15/14 | 10/11 | 5/3 | |
| Number of IRL (f/m) | – | 166 (46/120) | – | |
| Age, years | 38 (22–69) | 38 (22–60) | 36 (22–69) | |
| Disease duration, years | 11 (5–40) | 11 (5–37) | 12.5 (6–40) | |
| Disease course (RRMS/SPMS) | 24/5 | 17/4 | 7/1 | |
| EDSS | ||||
| Baselinea (n = 29/21/8)b | 2 (0–8) | 2 (0–7.5) | 1.5 (0–8) | |
| 1yr FUa (n = 27/19/8)b | 2 (0–8) | 2 (0–7.5) | 2 (0–8) | |
| At sNfL measure 3yr FU (n = 27/19/8) b | 2 (0–8) | 2 (0–8) | 2 (0–8) | |
| MSSS | ||||
| At 1yr FUa (n = 26/19/7)b | 1.3 (0.11–7) | 1.4 (0.2–7) | 1.1 (0.1–5) | |
| At sNfL measure 3yr FU (n = 26/19/7)b | 1.8 (0.1–7) | 1.7 (0.2–7) | 2.8 (0.1–5) | |
| Relapse count | ||||
| Baselinea (n = 29/21/8)b | 0 (0–2) | 0 (0–2) | 0 (0–1) | |
| 1yr FUa (n = 28/20/8)b | 0 (0–2) | 0 (0–2) | 0 (0–1) | |
| Treatment (none/first-line/second line) | ||||
| Baselinea | 5/14/10 | 3/10/8 | 2/4/2 | |
| 1yr FUa | 7/13/9 | 5/9/7 | 2/4/2 | |
| 9-HPT, (r/l) | ||||
| Baselinea (n = 28/20/8)b | 20.9 (15.6–41.1)/22.8 (15.95–43.6) | 21.4 (15.7–41.1)/23.3 (15.9–43.6) | 20.08 (17.1–34.7)/21.2 (16.5–34.4) | |
| 1yr FUa (n = 27/19/8)b | 20.4 (14.2–39.4)/21.9 (15.4–85.8) | 20.2 (15.7–39.4)/21.9 (15.4–85.8) | 21.1 (14.2–33.1)/19.8 (16.7–35.3) | |
| T25FW | ||||
| Baselinea (n = 27/20/7)b | 5.5 (4.2–16.4) | 5.4 (4.2–16.4) | 5.6 (5.3–7.4) | |
| 1yr FUa (n = 25/18/7)b | 5.9 (4.1–18.0) | 5.8 (4.1–18.0) | 6.0 (4.9–9.5) | |
| SDMT z-score | ||||
| Baselinea (n = 29/21/8)b | 0 (−3 to 1.5) | −0.5 (−3 to 1.5) | 0 (−2 to 1) | |
| 1yr FUa (n = 27/19/8)b | 0 (−3 to 2.5) | −0.5 (−3 to 2.5) | 1.25 (−2.5 to 2) | |
| sNfL (pg/ml) | ||||
| Baseline (n = 27/19/8)b | 5.7 (3.2–23.7) | 7.6 (3.3–19.2) | 4.4 (3.2–23.72) | 0.045 |
| 3yr FU (n = 28/20/8)b | 8.0 (3.8–21.5) | 8.8 (5.2–21.5) | 6.1 (3.8–19.8) | |
| FLAIR lesion count; n = (29/21/8)b | 30 (2–98) | 32 (5–98) | 11.5 (2–64) | 0.047 |
| MP2RAGE non-IRL lesion count; n = (29/21/8)b | 20 (1–135) | 23 (3–115) | 11.5 (1–135) | |
| MP2RAGE IRL lesion count; n = (29/21/8)b | – | 3 (1–41) | – | |
| MP2RAGE Non-IRL lesion volume, ml; n = (29/21/8)b | 29.4 (0.8–439.9) | 31.4 (2.4–241.9) | 14.4 (0.8–439.9) |
All values are given in median (range).
Values refer to the time point of the neuropsychological testing at baseline and 1yr FU.
Numbers in brackets indicate the number of patients grouped according to the column categories (total cohort, IRL, and non-IRL).
The p-values < 0.05 indicate significant results and are marked in boldface.
BL, baseline; EDSS, Expanded Disability Status Scale; f, female; FLAIR, fluid-attenuated inversion recovery; FU, follow-up; IRL, iron rim lesion; m, male; MP2RAGE, magnetization Prepared RApid Gradient Echo; MSSS, Multiple Sclerosis Severity Score; r, range; RRMS, relapsing-remitting multiple sclerosis; SDMT, Symbol Digit Modality Test; sNfL, serum neurofilament light chain; SPMS, secondary-progressive multiple sclerosis; SWI, susceptibility-weighted images; yr, year; 9HPT, Nine-Hole-Peg-Test; T25FW, timed 25-foot walk test; r/l, right hand/left hand.